Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and acquired resistance. There are likely many genetic causes, and recent studies suggest the important role of ESR1 mutations and fusions in endocrine resistance. Previously, we reported a recu...
Alternative Titles
Full title
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_dd3f224ecac34744833aac2245b2fd71
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dd3f224ecac34744833aac2245b2fd71
Other Identifiers
ISSN
1465-542X,1465-5411
E-ISSN
1465-542X
DOI
10.1186/s13058-020-01325-3
